Latest News
Spyre Therapeutics, Inc.
- Spyre Therapeutics, Inc Estimates – XETR:3920
- Las ETF que invierten en acciones de Spyre Therapeutics, Inc
- Spyre Therapeutics unveils clinical data on new IBD antibody therapies at UEGW 2026.
- Why is Spyre Therapeutics stock rallying today?
- Spyre launches stock sale to fund new SPY072 late-stage program
- KymaThera, Rouge raise VC funding; Vaxcyte, Spyre do public offerings
- Why is Spyre Therapeutics stock sliding today?
- Spyre Therapeutics announces proposed public offering of common stock
- Spyre Therapeutics prices $350M public offering at $85 per share
- Spyre Therapeutics’ chief legal officer sells $2.63m in shares By Investing.com
- Spyre Therapeutics CFO Scott Burrows sells $2.26m in stock
- Why is Spyre Therapeutics stock climbing today?
Headlines from the last 30 days, linking to the original publishers. See all market news →